ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY SHARES
ADAPTIMMUNE THERAPEUTICS PLC - AMERICAN DEPOSITARY SHARES
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical tr... ials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Industry:
Company
Address:
60 Jubilee Avenue, Abingdon, United Kingdom Zipcode OX14 4RX
Country:
United Kingdom
Phone:
44 12 3543 0000
Market Cap:
788.29MTotal Revenue:
3.96MTotal Assets:
451.14MTotal Cash:
56.88M
Subsidiary: Adaptimmune Limited
Website Url:
http://www.adaptimmune.com
Key Executives
| Name | Title | Pay | Year Born |
|---|---|---|---|
| Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 720,857$ | 1972(48 years old) |
| Dr. Helen Katrina Tayton-Martin | Co-Founder & Chief Bus. Officer | 588,190$ | 1967(53 years old) |
| Mr. William C. Bertrand Jr. | Chief Operating Officer | 602,613$ | 1965(55 years old) |
| Mr. Gavin Hilary James Wood BA (Hons), ACA | Chief Financial Officer | N/A | 1970(50 years old) |
| Mr. Sébastien Desprez | VP of Communications & Investor Relations | N/A | N/A |
| Ms. Margaret Henry | Head of PR & Company Sec. | N/A | N/A |
| Dr. Rafael G. Amado | Pres of R&D | N/A | 1964(56 years old) |
| Dr. Arundathy Nirmalini Pandite M.B.A., M.D. | Sr. VP of Clinical Devel. | N/A | 1959(61 years old) |
| Trupti Trivedi | Head of Biometrics and VP | N/A | N/A |
| Prof. P. Julian Dyson Ph.D. | Head of Autoimmune Group | N/A | N/A |
Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST According to Adaptimmune Therapeutics Plc - American Depositary Shares's financial reports the company's revenue in 2020 were 3.96M an increase( +200%) over the years 2019 revenue that were of 1.12M. In 2020 the company's total earnings were -130.09M while total earnings in 2019 were -137.16M(-5.11%). Company's stock symbol is ADAP. Lastest price : 5.07. Total volume :389.54k Click reload if you want to check the lastest price on market!!!
Site Inspections: http://www.adaptimmune.com
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Adaptimmune Therapeutics Plc - American Depositary Shares" on Search Engine
Adaptimmune Therapeutics plc American Depositary Shares
Nasdaq.com Adaptimmune Therapeutics plc American Depositary Shares (ADAP) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Adaptimmune Therapeutics plc Proposes Public Offering of
Finance.yahoo.com Jun 01, 2020 · Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced...
Adaptimmune Therapeutics plc Proposes Public Offering of
Finance.yahoo.com Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy to …
Adaptimmune Therapeutics plc Proposes Public Offering of
Globenewswire.com Jun 01, 2020 · Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares Email Print Friendly Share June 01, 2020 06:00 ET | Source: Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc Prices Public Offering of
Globenewswire.com Jun 02, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today...
Adaptimmune Therapeutics plc Proposes Public Offering of
Markets.businessinsider.com Jun 01, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today ...
Adaptimmune Therapeutics plc Announces Closing of Public
Finance.yahoo.com Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American...
Adaptimmune Therapeutics plc Prices Public Offering of
Globenewswire.com Jan 22, 2020 · Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares Email Print Friendly Share January 22, 2020 08:48 ET | Source: Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc Prices Public Offering of
Finance.yahoo.com Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American...
Adaptimmune Therapeutics plc (ADAP)
Adaptimmune.com Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 Read Press Release Nov 20, 2020 • 7:30 AM EST
Adaptimmune Therapeutics plc Prices Public Offering of
Markets.businessinsider.com Jun 02, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today ...
Adaptimmune Therapeutics plc Proposes Public Offering of
Ih.advfn.com Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering.
Adaptimmune Therapeutics plc Prices Public Offering of
Adaptimmune.com Jan 22, 2020 · PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.00 per ADS.
FAQ :: Adaptimmune Therapeutics plc (ADAP)
Adaptimmune.com An American Depositary Share (ADS) is a US dollar-denominated share, evidenced by an ADR, which represents a specified number of underlying shares held in custody in the UK. Adaptimmune's ADSs, each representing 6 Ordinary Shares, are traded on the NASDAQ Stock Market under the ADAP symbol.
Adaptimmune Therapeutics plc American Depositary Shares
Nasdaq.com Find the latest Institutional Holdings data for Adaptimmune Therapeutics plc American Depositary Shares (ADAP) at Nasdaq.com.
Adaptimmune Therapeutics plc Announces Closing of Public
Markets.businessinsider.com Jun 04, 2020 · Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc Proposes Public Offering of
Adaptimmune.com Jun 01, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering.
ADAP:NASDAQ GS Stock Quote - Adaptimmune Therapeutics Plc
Bloomberg.com Shares Outstanding 155.47M. Price to Book Ratio 13.7451. Price to Sales Ratio 1,111.9003. 1 Year Return 67.77%. ... Adaptimmune Therapeutics plc is a …
Adaptimmune Therapeutics plc Announces Closing of Public
Adaptimmune.com Jun 04, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).
Adaptimmune Therapeutics plc Announces Closing of Public
Globenewswire.com Jan 24, 2020 · PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today...
Adaptimmune Therapeutics plc Announces Registered Direct
Globenewswire.com Sep 05, 2018 · Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares Email Print Friendly Share September 05, 2018 07:30 ET | Source: Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc American Depositary Shares
Nasdaq.com Find the latest Insider Activity data for Adaptimmune Therapeutics plc American Depositary Shares (ADAP) at Nasdaq.com.
Adaptimmune Therapeutics plc Prices Public Offering of
Ca.finance.yahoo.com Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional ...
Adaptimmune Therapeutics PLC (Form: F-6, Received: 04/27)
Content.edgar-online.com Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Deposit Agreement, by and among Adaptimmune Therapeutics plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder ...
BRIEF-Adaptimmune Proposes Public Offering Of American
Reuters.com Jun 01, 2020 · * adaptimmune therapeutics plc proposes public offering of american depositary shares * adaptimmune therapeutics - intends to offer and sell 12.5 million american depositary shares in underwritten ...
BRIEF-Adaptimmune Therapeutics PLC Prices Public Offering
Reuters.com * adaptimmune therapeutics plc prices public offering of american depositary shares * adaptimmune therapeutics - announced pricing of underwritten public offering of 20,500,000 of its adss at ...
Adaptimmune Therapeutics plc Proposes Public Offering of
Ca.finance.yahoo.com Jun 01, 2020 · Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or ...
Adaptimmune Therapeutics plc American Depositary Shares
Nasdaq.com Feb 25, 2021 · Find the latest press releases from Adaptimmune Therapeutics plc American Depositary Shares (ADAP) at Nasdaq.com.
Adaptimmune Therapeutics plc Announces Closing of Public
Bloomberg.com Jan 25, 2020 · Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune ...
Adaptimmune Therapeutics plc Announces Closing of Public
Sg.finance.yahoo.com Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters ...
Adaptimmune Therapeutics plc Prices Public Offering of
Benzinga.com Jun 02, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(NASDAQ:ADAP), a leader in cell therapy to treat cancer, today announced ...
Adaptimmune Therapeutics PLC (Form: F-6EF, Received: 07/28)
Content.edgar-online.com Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among Adaptimmune Therapeutics plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies ...
Adaptimmune Therapeutics plc Announces Closing of Public
Apnews.com Jun 04, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold a total of ...
www.sec.gov
Sec.gov Aug 10, 2020 · ADAPTIMMUNE THERAPEUTICS PLC $200,000,000 AMERICAN DEPOSITARY SHARES each representing 6 Ordinary Shares SALES AGREEMENT . August 10, 2020 . Cowen and Company, LLC. 599 Lexington Avenue. New York, NY 10022 . Ladies and Gentlemen: Adaptimmune Therapeutics plc (the “Company”), confirms its agreement (this “Agreement”) with Cowen and ...
Adaptimmune Therapeutics plc Announces Full Exercise and
Markets.businessinsider.com Feb 07, 2020 · Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares PRESS RELEASE GlobeNewswire Feb. …
Adaptimmune Therapeutics plc Prices Public Offering of
Uk.finance.yahoo.com Jun 02, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”) at a price to the public of $11.00 per ADS.
Adaptimmune Therapeutics PLC (Form: 8-A12B, Received: 04)
Content.edgar-online.com Adaptimmune Therapeutics plc (Exact name of registrant as specified in its charter) ... “Dividends and Dividend Policy,” “Description of Share Capital and Articles of Association,” “Description of American Depositary Shares,” “Ordinary Shares and ADSs Eligible For Future Sale” and “Taxation” of the prospectus included as ...
Adaptimmune Therapeutics plc Proposes Public Offering of
Marketscreener.com PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering.
Adaptimmune Therapeutics PLC (Form: F-1/A, Received: 04/27)
Content.edgar-online.com This is Adaptimmune Therapeutics plc's initial public offering. We are selling American Depositary Shares, or ADSs. Each ADS represents 6 ordinary shares, par value £0.001 per share. We expect the public offering price to be between $15.00 and $17.00 per ADS. Currently, no public market exists for the ADSs or ordinary shares.
www.sec.gov
Sec.gov Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among Adaptimmune Therapeutics plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies ...
ADAP Adaptimmune Therapeutics plc Stock Quote
Finviz.com Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters Option to Purchase Additional American Depositary Shares. GlobeNewswire. Feb-05-20 11:30AM : Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year? Zacks +11.39%. Feb-03-20 09:13AM : Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can ...
Adaptimmune Therapeutics plc Announces Closing of Public
Marketscreener.com PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).
Unassociated Document - SEC.gov | HOME
Sec.gov Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Deposit Agreement, by and among Adaptimmune Therapeutics plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder ...
SEC.gov | HOME
Sec.gov Adaptimmune Therapeutics plc (a public limited company incorporated under the laws of England and Wales) 20,500,000 American Depositary Shares . Representing an Aggregate of . 123,000,000 Ordinary Shares . UNDERWRITING AGREEMENT . June 1, 2020 . Cowen and Company, LLC. 599 Lexington Avenue. New York, NY 10022 . SVB Leerink LLC. 1301 Avenue of ...
BRIEF-Adaptimmune Therapeutics announces registered direct
Reuters.com Apr 05, 2017 · April 5 (Reuters) - Adaptimmune Therapeutics Plc * Adaptimmune therapeutics - entered agreement with matrix capital management co lp to buy about us$42 million of its american depositary shares
Adaptimmune Therapeutics plc Proposes Public Offering of
Uk.finance.yahoo.com Jun 01, 2020 · PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market …
Unassociated Document - SEC
Sec.gov Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among Adaptimmune Therapeutics plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies ...